A closely watched experimental treatment for a leading cause of blindness slowed the death of retinal cells in a large, late-stage study, a finding that the drug's maker, Apellis Pharmaceuticals, said Thursday will support an application to the Food and Drug Administration for approval.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,